126 related articles for article (PubMed ID: 21954059)
1. Discovery of the improved antagonistic prolactin variants by library screening.
Liu Y; Gong W; Breinholt J; Nørskov-Lauritsen L; Zhang J; Ma Q; Chen J; Panina S; Guo W; Li T; Zhang J; Kong M; Liu Z; Mao J; Christensen L; Hu S; Wang L
Protein Eng Des Sel; 2011 Nov; 24(11):855-60. PubMed ID: 21954059
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
3. Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists.
Tan D; Chen KE; Khoo T; Walker AM
Cancer Lett; 2011 Nov; 310(1):101-8. PubMed ID: 21775057
[TBL] [Abstract][Full Text] [Related]
4. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
5. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
6. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
9. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone.
van Agthoven J; Zhang C; Tallet E; Raynal B; Hoos S; Baron B; England P; Goffin V; Broutin I
J Mol Biol; 2010 Nov; 404(1):112-26. PubMed ID: 20875426
[TBL] [Abstract][Full Text] [Related]
11. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro.
Langan EA; Ramot Y; Hanning A; Poeggeler B; Bíró T; Gaspar E; Funk W; Griffiths CE; Paus R
Br J Dermatol; 2010 May; 162(5):1127-31. PubMed ID: 20302576
[TBL] [Abstract][Full Text] [Related]
12. Development of prolactin receptor antagonists with reduced pH-dependence of receptor binding.
Hansen MJ; Olsen JG; Bernichtein S; O'Shea C; Sigurskjold BW; Goffin V; Kragelund BB
J Mol Recognit; 2011; 24(4):533-47. PubMed ID: 20842635
[TBL] [Abstract][Full Text] [Related]
13. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.
Jacobson EM; Hugo ER; Tuttle TR; Papoian R; Ben-Jonathan N
Trends Endocrinol Metab; 2010 Nov; 21(11):691-8. PubMed ID: 20846877
[TBL] [Abstract][Full Text] [Related]
14. New concepts in prolactin biology.
Bernichtein S; Touraine P; Goffin V
J Endocrinol; 2010 Jul; 206(1):1-11. PubMed ID: 20371569
[TBL] [Abstract][Full Text] [Related]
15. The many faces of prolactin in breast cancer.
Chen WY
Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland.
Hovey RC; Trott JF; Ginsburg E; Goldhar A; Sasaki MM; Fountain SJ; Sundararajan K; Vonderhaar BK
Dev Dyn; 2001 Oct; 222(2):192-205. PubMed ID: 11668597
[TBL] [Abstract][Full Text] [Related]
17. Prolactin and the prolactin receptor: new targets of an old hormone.
Harris J; Stanford PM; Oakes SR; Ormandy CJ
Ann Med; 2004; 36(6):414-25. PubMed ID: 15513293
[TBL] [Abstract][Full Text] [Related]
18. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
19. Identification of gain-of-function variants of the human prolactin receptor.
Goffin V; Bogorad RL; Touraine P
Methods Enzymol; 2010; 484():329-55. PubMed ID: 21036240
[TBL] [Abstract][Full Text] [Related]
20. The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications.
Goffin V; Touraine P
Expert Opin Ther Targets; 2015; 19(9):1229-44. PubMed ID: 26063597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
